Safety Alerts & Recalls
What does this mean?
This recall for Trizivir (abacavir sulfate 300mg, lamivudine 150 mg and zidovudine 300 mg) Tablets was issued at a warehouse and pharmacy level only. The FDA and the manufacturer have determined that any recalled product that may have been dispensed to patients does not pose a significant health risk.
However, if you or someone your care for takes Trizivir, it’s a good idea to check your prescription. If you notice more than one type of tablet or tablets that look different than what you expect, please take your prescription bottle and tablets to your pharmacy to examine and possibly exchange.
If you take Trizivir and are concerned or if think you are experiencing side effects from your medicine, you should speak to your doctor.
GlaxoSmithKline Recalls Single Lot of Trizivir Tablets
GlaxoSmithKline has recalled a single lot of Trizivir (abacavir sulfate 300mg, lamivudine 150 mg and zidovudine 300 mg) Tablets. Lot number 0ZP5128 has been recalled because the tablets on this lot may contain both Trizivir tablets and Lexiva 700 mg tablets. Trizivir contains the active ingredient abacavir, lamivudine and zidovudine and is commonly used in the treatment of HIV. Lexiva is another medicine used to treat human immunodeficiency virus (HIV) infection.
This recall alert only applies to the single/select lot of Trizivir (abacavir sulfate 300mg, lamivudine 150 mg and zidovudine 300 mg) Tablets. No other abacavir, lamivudine and zidovudine products were involved in this recall.
To view the FDA notice about this recall, please visit: more information here